Table 1 Baseline characteristics of patients with retroperitoneal leiomyosarcoma (RLS) before and after propensity score matching (PSM).

From: Association of surgical resection with survival in retroperitoneal leiomyosarcoma based on SEER propensity score matching and machine-learning models

Variable

Before matching

After matching

All (n = 1,041)

No surgery (n = 224)

Surgery (n = 817)

P

All (n = 318)

No surgery (n = 159)

Surgery (n = 159)

P

Age, n (%)

   

 < 0.001

   

0.084

 ≤ 60 years

494 (47.5)

76 (33.9)

418 (51.2)

 

93 (29.2)

54 (34.0)

39 (24.5)

 

 > 60 years

547 (52.5)

148 (66.1)

399 (48.8)

 

225 (70.8)

105 (66.0)

120 (75.5)

 

Race, n (%)

   

0.031

   

0.952

White

732 (70.3)

146 (65.2)

586 (71.7)

 

221 (69.5)

110 (69.2)

111 (69.8)

 

Black

201 (19.3)

57 (25.4)

144 (17.6)

 

68 (21.4)

35 (22.0)

33 (20.8)

 

Other

108 (10.4)

21 (9.4)

87 (10.6)

 

29 (9.1)

14 (8.8)

15 (9.4)

 

Sex, n (%)

   

0.011

   

0.525

Male

277 (26.6)

75 (33.5)

202 (24.7)

 

84 (26.4)

45 (28.3)

39 (24.5)

 

Female

764 (73.4)

149 (66.5)

615 (75.3)

 

234 (73.6)

114 (71.7)

120 (75.5)

 

Differentiation grade, n (%)

   

 < 0.001

   

0.853

I/II

252 (24.2)

22 (9.8)

230 (28.2)

 

43 (13.5)

21 (13.2)

22 (13.8)

 

III/IV

438 (42.1)

71 (31.7)

367 (44.9)

 

114 (35.8)

55 (34.6)

59 (37.1)

 

Unknown

351 (33.7)

131 (58.5)

220 (26.9)

 

161 (50.6)

83 (52.2)

78 (49.1)

 

SEER summary stage, n (%)

   

 < 0.001

   

0.351

Localized

305 (29.3)

28 (12.5)

277 (33.9)

 

61 (19.2)

25 (15.7)

36 (22.6)

 

Regional

301 (28.9)

48 (21.4)

253 (31.0)

 

82 (25.8)

41 (25.8)

41 (25.8)

 

Distant

180 (17.3)

79 (35.3)

101 (12.4)

 

78 (24.5)

44 (27.7)

34 (21.4)

 

Unknown

255 (24.5)

69 (30.8)

186 (22.8)

 

97 (30.5)

49 (30.8)

48 (30.2)

 

Radiotherapy, n (%)

   

 < 0.001

   

0.137

No

694 (66.7)

176 (78.6)

518 (63.4)

 

227 (71.4)

120 (75.5)

107 (67.3)

 

Yes

347 (33.3)

48 (21.4)

299 (36.6)

 

91 (28.6)

39 (24.5)

52 (32.7)

 

Chemotherapy, n (%)

   

 < 0.001

   

0.820

No

737 (70.8)

107 (47.8)

630 (77.1)

 

187 (58.8)

95 (59.7)

92 (57.9)

 

Yes

304 (29.2)

117 (52.2)

187 (22.9)

 

131 (41.2)

64 (40.3)

67 (42.1)

 
  1. SEER, Surveillance, Epidemiology, and End Results; PSM, propensity score matching.
  2. P-values from χ2 tests comparing surgery vs no surgery within each period (before or after matching). Percentages may not total 100% due to rounding.
Back to article page